NIPA Hardwicke seeking PCMX topical antimicrobial Category I status.
This article was originally published in The Tan Sheet
Executive Summary
NIPA HARDWICKE PCMX ANTIMICROBIAL STUDY TO TEST METABOLISM of the topical ingredient, which is also called chloroxylenol, in mice in accord with guidelines established at a Sept. 22 FDA "feedback" meeting in Rockville, Md. FDA Anti-infective Drug Products Pharmacology/Toxicology Reviewer Terry Peters suggested the Wilmington, Del.-based chemical manufacturer NIPA Hardwicke should use carbon 14, a radioactive isotope, to chart the topical antimicrobial ingredient's metabolic changes during a four-week repeated application, absorption, digestion, metabolism and excretion (ADME) study.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning